Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — AMA Study Concludes Cannabis Legalization Doesn’t Increase Psychosis Prevalence

A recent study published by the American Medical Association has revealed that there has been no notable increase in the number of diagnoses for psychosis in states where cannabis is legal compared to those where it is not. To investigate the possibility that cannabis legalization could be associated with higher rates of psychosis, which some prohibitionists have used as evidence against legalization, researchers at Pennsylvania University, Stanford University and the Department of Veterans Affairs examined data on more than 63 million beneficiaries of health insurance from 2003 to 2017.

The authors examined Medicare Advantage and commercial claims data in particular to evaluate the possible effects of cannabis legalization, which has been shown in some studies to increase adult usage rates. The researchers claim that the study was the largest and first to measure the relationship between the prevalence of health care related to psychosis claims throughout U.S. states and medical and recreational marijuana policies.

The findings, according to Deputy Director of NORML Paul Armentano, are “reassuring,” but he warned that it’s crucial to understand that some populations who are inclined to psychosis will likely be more susceptible than others to suffering negative effects from marijuana use. The study notes that it may be instructive to keep an eye on psychosis as a possible side effect of state-level marijuana legalization as more states introduce new policies.

While the notion of a connection between cannabis and psychosis is frequently raised in arguments made by proponents of prohibition against reform initiatives, writer Alex Berenson has established himself as one of the leading activists for the idea. His other assertions that cannabis use is linked to violent behavior were referenced in a 2019 study that was funded by the federal government, which found that legalization had a very minor effect on property crime violence.

Another recent government-funded study found that residents of states with legalized recreational marijuana have lower rates of alcohol use disorder than residents of states where marijuana is still illegal. In addition, another AMA study found that two in six people with chronic pain use cannabis as a pain relief option, with the majority of those people substituting cannabis for other painkillers such as opioids.

At the same time, another study published by the association concluded that legalizing medical cannabis at the state level is linked to a marked decline in prescription and opioid use among specific cancer patients.

With such results pointing to some of the implied benefits of legalizing cannabis, many more firms are likely to join the space and leverage the funding accessible through companies such as REZYFi Inc. in order to scale their operations and develop innovative offerings for customers.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

  • Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs
  • DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes
  • The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing
  • DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending

Speaking during a late 2022 interview (https://cnw.fm/w4qAD), Chris Bunka, the Chairman and CEO of Lexaria Bioscience (NASDAQ: LEXX), emphasized the varied applications of DehydraTECH(TM), and that, for example, the company intends to help people quit smoking by enabling them to satisfy their nicotine cravings in a way that will not kill them: pouches. This comes against a backdrop of worrying statistics, which show that over 480,000 people in the United States (https://cnw.fm/x4FoR) and over 8 million people globally (https://cnw.fm/64clk) die annually from cigarette smoking.

Lexaria also sees an opportunity to help people with hypertension, which affects about 116 million people in the US (https://cnw.fm/lU3oV) and seizure disorders, which affect 3.4 million people in the US and 65 million globally (https://cnw.fm/tn9sT). “We really do believe Lexaria is going to make the world a better place,” Bunka emphasized in closing.

The company’s belief in a better tomorrow is anchored in its patented DehydraTECH technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs available in various formats, including oral ingestible, oral buccal/sublingual, and topical products. According to Lexaria, its technology “is best thought of as an additional layer that improves the effectiveness of existing or planned new products for companies that offer consumer supplements, prescription and non-prescription-based drugs, and nicotine products” (https://cnw.fm/Q8wZn).

When analyzed in terms of numbers, the improvements are impressive. Having conducted both in vitro and in vivo studies, Lexaria has established that DehydraTECH increases intestinal bioabsorption of certain bioactive compounds by as much as 27 times. Furthermore, given the technology increases the quantity of each active ingredient delivered to the blood plasma and brain, it reduces the need for high doses, ultimately contributing to lower overall drug costs as lower doses can still achieve the same or even better results.

In addition, the technology works rapidly, with the DehydraTECH formulations’ effects becoming prominent in as little as 1.5 minutes post-administration. Other benefits include masked taste and smell of the active molecules, which has the intended effect of helping manufacturers create low-sugar products with fewer calories and avoid using artificial sweeteners.

Manufacturers can also register other benefits, especially considering the process is very cost-effective, according to the company. “Micro quantities of fatty acids (Generally Recognized as Safe, or GRAS, ingredients) are incorporated into drugs, consumer packaged goods, and capsule products at a fraction of a penny per serving,” the company’s website reads. “DehydraTECH technology works with process equipment readily found in most commercial kitchen/production facilities, is easily utilized under GMP certification as needed, and is highly scalable.”

The technology, which is protected by a robust suite of 28 patents granted worldwide (https://cnw.fm/YAfXW), has so far been used to enhance the capabilities of cannabidiol (“CBD”), nicotine, antivirals, and PDE5 inhibitors, to mention a few, with pharmacokinetic studies evaluating the resultant formulations showing positive results.

The recently completed HYPER-H21-4 study, for instance, which evaluated DehydraTECH-CBD as a potential treatment against hypertension, showed that the formulation resulted in statistically significant lowering of 24-hour ambulatory blood pressure as well as sustained blood pressure reduction (https://cnw.fm/mnuiU). HYPER-H21-3 showed attenuated pulmonary artery systolic pressure (https://cnw.fm/Seypt), while HYPER-H21-2 evidenced up to a 23% reduction in overnight blood pressure and reduced arterial stiffness (https://cnw.fm/4mhsF). Lexaria is currently preparing the paperwork needed to file an Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”) as a precursor to commencing registered clinical trials.

Separately, in an animal study, Lexaria showed that DehydraTECH-nicotine delivered through the mucous membrane in the mouth resulted in a 10-20x reduction in time to deliver peak levels of nicotine to the bloodstream and 2-3x higher levels of nicotine in the blood (https://cnw.fm/oXHqY). In yet another animal study comparing DehydraTECH-CBD to Epidiolex(R), the first and only FDA-approved CBD medication for the treatment of seizures, Lexaria observed that its formulation appeared to demonstrate effectiveness at lower doses and more rapidly than Epidiolex (https://cnw.fm/geeqh).

By targeting conditions and spaces that affect millions of lives, Lexaria is indeed working to make the world a better place, alleviating the suffering of scores of people.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — FDA Passes the Buck, Gives Congress Plenty to Consider About CBD Marketing

The current tense situation regarding CBD-containing products will be maintained for the time being as a result of the U.S. Food and Drug Administration’s recent announcement that it will not regulate those products, instead delegating that responsibility to Congress. This adds to the workload for a Congress that is already becoming more acrimonious and creates more uncertainty for businesses considering entering the $4 billion-plus CBD market.

Congress must make decisions regarding intoxicating cannabinoids derived from hemp, such as delta-10 THC and delta-8, in addition to tackling broader cannabis policy reform, which includes banking access, tax relief and the issue of federal legalization.

For the time being, the FDA has largely stayed out of the CBD product market, sending enforcement letters only to businesses that advertise goods using false medical claims in violation of the federal Food, Drug and Cosmetic Act.

While Congress is negotiating a new iteration of the 2018 Farm Bill, which is set to expire this year, one of the issues that could be resolved is whether cannabinoids should be allowed in drinks, gummies or other products. The bill, an extensive piece of legislation ratified as a law by former President Donald Trump, legalized hemp production throughout the country. It also paved the way for the CBD boom and the emergence of new, hemp-derived intoxicating cannabinoids.

Since then, the FDA has been tasked with determining how to regulate a flood of hemp-derived CBD and other cannabinoid-containing products. Last week, however, the FDA decided against regulation, claiming that its current regulatory frameworks were insufficient and that Congress should instruct the FDA on what to do.

Trade organizations that represent producers of hemp products and hemp growers expressed their disappointment with the FDA’s announcement; the groups had hoped that the agency would have provided clear guidelines rather than putting the issue on hold. For now, existing product manufacturers will continue to be in a state of uncertainty.

The FDA may be selected by Congress as the appropriate agency to oversee cannabis products or Congress may decide that a completely new agency should be in charge of overseeing hemp-derived cannabinoids, which is another unintended but unavoidable consequence of the farm bill revision that has now been added to Congress’s growing list of things to do.

Several jurisdictions, such as Colorado and Utah, have adopted marijuana-like regulations for hemp products.

For enterprises such as India Globalization Capital Inc. (NYSE American: IGC) that lean toward the medicalization of cannabis, there is a clear process to follow in order to obtain FDA approval for any formulations that are developed. For that reason, companies of this nature don’t need to be concerned about the FDA’s efforts to throw back the regulatory guidance task to Congress on matters of CBD supplements.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Plan to Legalize Cannabis in Germany Could Be Delayed Beyond 2024

In late October, the German government approved plans to legalize marijuana within the country’s borders. The legislation would have allowed individuals aged 18 years and older to purchase cannabis from federally licensed cannabis stores and pharmacies, possess up to 20 grams of cannabis flower and grow up to three plants at home for recreational use.

At the time, officials said that the legislation’s passage depended on whether the European Commission would approve the bill. Germany’s deference to European and international bodies meant that the bill had to be in line with European and international policy before the Federal Cabinet could push forward with legalization.

However, months after Health Minister Karl Lauterbach announced the bill’s approval, the German government still hasn’t submitted it to the European Union for review and approval. According to a statement from Lauterbach, the legislation is “currently being drafted” by the federal authorities. He noted that lawmakers have to address significant  operational and legal questions surrounding the implementation of a legal cannabis market, and this requires time and coordination between the affected ministries.

It is unlikely that German lawmakers will finish drafting the bill and submit it to the European Union in time for legalization in 2024.

On top of allowing cannabis consumption, the bill would also have suspended or closed any cannabis-related offenses. It would place a ban on marijuana advertising and prevent consumers from taking cannabis to a location that sells alcohol and tobacco.

Lauterbach stated in 2022 that lawmakers would file the legislation in the first quarter of 2023, but he added that he doesn’t expect a fast-track approval process. In his recent statement, Lauterbach noted that the government’s goal of controlled cannabis dispensing was meant to preserve consumer health, protect children and youths, tackle drug-related crime and address the black market.

The legislation is quite unprecedented in Europe and would make Germany among the first countries aside from Malta and Luxembourg to launch such a legal cannabis market. However, the legislation has been subject to tons of scrutiny and may not receive the go-ahead from European and international authorities.

Except for Malta, which legalized recreational cannabis in 2021, marijuana is illegal to produce, sell and use in most of Europe thanks to its conservative stance on cannabis.

Countries such as Portugal, the Netherlands and Austria have decriminalized low-level cannabis possession, but efforts by Luxembourg to legalize cannabis in 2018 were hampered by the EU’s relatively conservative cannabis laws. If Germany convinces the EU to depart from its conservative cannabis policies, many more EU countries interested in legalization may follow suit.

As legalization spreads in different regions of the globe, innovative financial solutions such as those offered by REZYFi Inc. could see heightened demand as industry companies look for ways to fund their growth and expansion.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi, Inc. are available in the company’s newsroom at https://cnw.fm/REZY

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

REZYFi, Inc. Anticipates Increased Demand for its Services Following Rise in Mortgage Demand

  • 30-year fixed-rate mortgages with conforming loan balances of $726,200 or less, saw rates decrease from 6.42% to 6.23% for the week ending January 18, 2023, resulting in a 28% increase in mortgage application volume, and a 34% increase in refinance demand
  • It is projected that by the end of 2023, mortgage rates in the country will drop by 5.25%, coming from 2022, which saw home financing costs nearly double
  • These rate drops present an opportunity for REZYFi to grow its customer reach, market share, and revenue but also offer an avenue for the growth of the housing finance sector

REZYFi, a growth mortgage origination and specialized financing company based in the United States is set to see a growth in the demand for its services in response to the changing financing market that has seen a drop in interest rates in the past few weeks. January 18, 2023, saw mortgage rates hit the lowest level since September 2022, and the market reacting with an increased demand for mortgages (https://cnw.fm/gaAX0).

Rates decreased from 6.42% to 6.23% for the average 30-year fixed-rate mortgages with conforming loan balances of $726,200 or less. In turn, mortgage application volume grew by nearly 28%, while refinance demand increased by 34% on the week ending January 21 compared to the previous week. In addition, it is projected that as more homes are listed on the market, the rates could go even lower, resulting in a further increase in mortgage demand.

“As we enter the beginning of the spring season, lower mortgage rates and more homes on the market will help affordability for first-time homebuyers,” noted Mike Fratantoni, MBA’s senior vice president and chief economist.

As a company that offers origination, structures, and investments in first mortgage loans and alternative structured financings secured by commercial real estate properties, the recent developments are much welcome. Of note is the anticipated sustained increase in the additional demand for mortgages, particularly given that 2022 saw home financing costs nearly double. Furthermore, it is projected that by the end of the 2023 calendar year, mortgage rates in the United States will drop to 5.25%, according to Bankrate (https://cnw.fm/4bk3G). While it will not be anything like pre-pandemic lows, it would still be significant in making real estate ownership more accessible and affordable, which is something REZYFi is looking to achieve.

The growing acceptance of cannabis-derived products and the support the industry has received so far are an opportunity for REZYFi and an avenue for the growth of the finance sector. The conversation surrounding the products and the companies that deal with cannabis has helped advance policy, creating an opportunity for companies such as REZYFi, and presenting customers with options. The dropping mortgage rates reflect an industry that is responding to the times. With this comes an even more significant opportunity for REZYFi to increase its customer reach, market share, and revenue.

Already, the company is positioning itself to cater to its target market and the challenges associated with lending to companies and individuals within the cannabis space. With the anticipated launch of its high-margin cannabis division and the development of proprietary technology, REZYFi is stamping its position as a market leader. But, more importantly, it is reaping the rewards of an industry that is slowly improving in performance and proving more accommodating, albeit slowly, to stakeholders in the cannabis space.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://cnw.fm/REZY

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

SideChannel Inc. (SDCH) Bringing Critical Security to Clients with Tailored Cybersecurity Programs for Mid-Market Companies

  • Brian recently joined Bell2Bell’s Stuart Smith in a podcast episode in which he discussed his and the company’s background, motivation to found SideChannel, existing market opportunities, 2022 milestones, and plans for 2023 and beyond
  • SideChannel, a provider of cybersecurity services and products, helps mid-market companies simplify cybersecurity
  • The company was founded in 2019 after CEO Brian Haugli observed a business opportunity in the largely underserved market
  • Over the years since, the company has grown, posting $4.8 million in revenue in 2022, up from $2.8 million in 2021

During his stints at the US Department of Defense (“DoD”) and Pentagon, and later upon entry into corporate America, Brian Haugli made an observation: US Government agencies and, crucially, large American corporations, relied on mid-market companies, innovative startups, and smaller organizations for important products and services. This reliance often meant that the security posture of the large companies and government agencies ultimately depended on the security posture of the smaller partner firms that had access to critical data. Unfortunately, cybersecurity products at that time were predominantly targeted at major enterprises, meaning most small and mid-sized businesses (“SMBs”) could not afford them. This left an underserved market and a massive business opportunity that SideChannel (OTCQB: SDCH) intended to capitalize on when it launched in 2019.

At the helm of the then-new startup was Brian, who now serves as the company’s CEO.  To ensure success, he surrounded himself with an executive team comprising people who also saw the existing gap, liked the business model he put together, and wanted to join him on the mission to building a program dedicated toward mid-market and small businesses, a market that is still underserved to date. And the journey has been, as he described in a recent interview with Bell2Bell’s Stuart Smith, “amazing.”

As part of the interview, Brian provided more information about the company’s evolution from its inception, touching on his and the company’s background, motivation to found SideChannel, existing market opportunities, 2022 milestones, and plans for 2023 and beyond (https://cnw.fm/vGAzt).

“Our job is to make cybersecurity simple and accessible. We are a cybersecurity firm with products and services, and we bring a wealth of experience from our collective backgrounds,” explained Brian. “Our focus is to bring real cyber security expertise, solid products and services, tech-enabled services into the types of companies that usually can’t actually afford full-time resources [and] the right types of resources. So, we’re predominantly focusing on the middle market and startups, and it’s been an underserved market.”

SideChannel, through its collective of expert virtual Chief Information Security Officers (“vCISOs”), builds and leads cybersecurity programs exclusively for SMBs. The vCISOs are attached to client companies where they own the cybersecurity budget, choose the right technological products for their needs, participate in hiring engineers and architects to deliver and execute within the cybersecurity programs, build the right processes, report to leadership about the goings on, and manage the programs over the long term. This long-term approach, according to Brian, sets SideChannel apart from the competition, which mostly only focuses on using technology to identify attacks or merely undertaking short-term assessments.

Coupled with the increased uptake of cybersecurity solutions due to the growing need by companies to protect themselves from cyberattacks and comply with cybersecurity regulations, this approach has contributed to tremendous growth for the company. In 2021, for example, SideChannel reported $2.8 million in revenue, a figure that grew to $4.8 million in 2022. And as a continued testament to the growth, the company is hiring more CISOs and people on its sales team as well as developing new services that best suit its client’s needs. “In February, we will post our [Form] 10Q, and you will see this rise and growth,” Brian continued.

The fiscal year 2022 saw the company not only post revenue growth but also announce the development of Enclave, a proprietary software product designed to provide network segmentation. According to Brian, this product creates an inventory of the assets within a networked environment, documenting everything that needs protection. It then isolates the various components that make up this environment, cordoning off attackers and helping reduce the damage an attacker can inflict on a system.

“We [created and launched Enclave] because we had a client base that told us this is what they needed. We did it because we knew that [asset inventory and segmentation of networks are] top controls to be addressed inside of all cybersecurity standards that are out there and frameworks that companies follow,” explained Brian. “And then, the products that are available in the marketplace are predominantly built for just the enterprise, which means the midmarket cannot afford the solution that everyone is saying they should be going for, and we are seeing people need.”

SideChannel expects to begin recognizing revenue from the Enclave product during the fiscal year 2023 (https://cnw.fm/14UEv). Still, the company also anticipates incorporating new features and capabilities into this product in addition to developing and launching other products to address systemic gaps that prevent mid-market clients from finding the right products.

The company also intends to evolve and develop its M&A strategy, which will see it bring under its umbrella operations that were previously outsourced to partners. “So, areas that we traditionally went to partners for, we will either be able to build those capabilities ourselves or acquire those capabilities or other resources from those partners and bring those in,” said Brian. “We are becoming Cybersecurity-as-a-Service for companies, and for us to have all those capabilities [under one umbrella], it gives our clients a one-stop-shop to [access] all these functions.”

And with companies increasingly recognizing the need for their vendors and B2B clients to safeguard their security posture, SideChannel is primed to articulate this need and manage that narrative to its customers’ customers.

“It is a niche. It is an area that is growing, and to date, I cannot say I have seen anybody else doing what we are doing, which is [exciting]. But we see a lot of other folks out there trying to do something similar, and we are beating them on capabilities and value,” Brain continued. “So, it tells me that there is an expanding need for this – we are not the only game in town. But it also tells me that we are doing it the way clients are looking for, not just reselling the product or some service out there. We are really bringing a lot of value to our clients, which they recognize.”

To listen to the full interview, please visit https://cnw.fm/7iZ8g

For more information, visit the company’s website at www.SideChannel.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — USDA Unveils First-Ever Weekly Report to Boost Hemp Market

The U.S. Department of Agriculture (USDA) announced last week that it will launch a weekly newsletter to promote the country’s nascent hemp industry by providing “unbiased, timely and accurate data” on hemp. The agency released the first edition of the National Hemp Report via its Agricultural Marketing Service in tandem with the announcement.

In a press release, USDA Under Secretary for Marketing and Regulatory Programs Jenny Lester Moffit stated that the USDA had seen the industry’s need for “timely market information.” She explained that the National Hemp Report would provide hemp industry stakeholders with weekly volume and price information to help them make good business decisions based on timely and accurate data.

The report, which is free and publicly available, covers weekly retail prices for hemp products along with hemp import volumes and weekly and yearly values of hemp imports into the United States. The publication is the first USDA market report dedicated to the hemp market. The USDA said that it would expand the report over time to incorporate additional market information.

Hemp became legal in the country after federal lawmakers approved the 2018 Farm Bill, removing hemp from the Controlled Substances Act and classifying it as an agricultural product. The legislation defined hemp as cannabis with less than 0.3% THC (the primary psychoactive compound in marijuana) and allowed farmers across the country to cultivate the plant under state and tribal programs.

In the years since legalization, America’s hemp industry has swiftly grown to a valuation of $1.3 billion in 2022 despite limited standardized policies and “patchwork regulations.” The new newsletter is a clear sign that federal regulators are taking a keener interest in the young hemp industry.

The report was released just a week after the USDA sent thousands of hemp farmers surveys as part of a yearly drive to learn more about the hemp industry’s evolution since the 2018 Farm Bill legalized the cultivation, distribution and sale of industrial hemp and its derivatives. This annual survey drive began in 2021 when the USDA asked a whopping 20,000 hemp farmers across the country to provide insight into the growing hemp market before releasing a report on its findings in 2022.

One year before the launch of the annual surveys, the USDA said that it would distribute a different survey nationally to collect data that could provide insight into how it would regulate the hemp industry. The USDA launched the survey in partnership with the University of Kentucky and the National Association of State Departments of Agriculture to learn about marketing practices, production practices and current production costs in the hemp market.

The growth of the hemp and marijuana industries has several trickle-down effects, such as boosting the demand for the products made by allied manufacturers such as Advanced Container Technologies Inc. (OTC: ACTX) that demand a thriving indoor cultivation segment to stay afloat.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — FDA Throws CBD Supplements Rulemaking Duty to Congress

Despite legislative requests from stakeholders, legislators and advocates, the FDA has stated that it will not develop regulations allowing the promotion of CBD as nutritional supplements, leaving the vast industry unregulated. After conducting a “careful study” of the nonintoxicating cannabinoid, the FDA concluded that CBD won’t be regulated along the same lines as food supplements. The agency stated that it would instead like to collaborate with Congress to gain a fresh perspective.

Meanwhile, the FDA is also rejecting three citizen petitions that asked for rulemaking regarding CBD marketing. Days prior to this announcement, the agency issued finalized guidelines outlining the procedure and particular factors for scientists to take into account when working with marijuana-based drugs, particularly marijuana and hemp.

The agency didn’t say that CBD shouldn’t be regulated; rather, it said that certain safety issues and information gaps make it impossible to regulate administratively under the laws in place at the moment. When necessary, the agency will collaborate with various governmental partners to take action regarding CBD and other cannabinoid products in order to protect the public.

In related news, the FDA rejected public petitions from the Consumer Healthcare Products Association, Council for Responsible Nutrition, and Natural Products Association for cannabidiol rulemaking. This comes as a drawback for those who have been pressing the FDA to take some kind of regulatory action on CBD and other hemp-based products because the market is still expanding quickly and there aren’t many safeguards in place.

Since industrial hemp and its products were made federally legal in the Farm Bill of 2018, the agency has come under pressure from trade associations and legislators on both sides to take action.  Leaders from the agency have in the past expressed their belief that Congress may need to work to effectively regulate CBD. Michael Bronstein, president of the American Trade Association for Cannabis and Hemp (ATACH), affirmed that the FDA’s findings regarding the regulatory framework for CBD products used in food, beverages and dietary supplements do indeed call for more Congressional action during a press release.

FDA chief Robert Califf agreed in the House oversight committee in May that the authority had moved sluggishly with the proposed rule for CBD regarding food production. To guide future rules, he said that the agency was taking measures to check into the tolerability of cannabidiol. However, he disagreed with the backlash from Congress over the agency’s failure to act, stating that he does not believe the existing policies on the food or narcotics sides are providing what is required to achieve the right trajectories forward.

This regulatory lacuna doesn’t affect entities such as India Globalization Capital Inc. (NYSE American: IGC) because they are focused on developing therapeutic formulations that meet the FDA’s requirements for any drug that is intended to be availed through the healthcare system.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Intensify Focus on Commercial Execution of its DehydraTECH Technology for the 2023 Calendar year

  • 2022 saw Lexaria introduce its patented DehydraTECH(TM) technology to world-leading collaborators while also exploring DehydraTECH-CBD for the potential treatment of hypertension
  • It also saw success in its research for the potential treatment of conditions such as epilepsy, making the year Lexaria’s most active one yet
  • Significant progress was made on key objectives in 2022, a feat which the company plans to capitalize on and leverage to scale up the commercial execution of its technology in 2023
  • To facilitate this, Lexaria has brought on board Julian Gangolli, former President of GW Pharmaceuticals USA, as a strategic advisor. Chris Bunka, Lexaria’s CEO, anticipates 2023 to be the “best year ever”

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has set its focus on the commercial execution of its robust patented DehydraTECH(TM) technology portfolio for the 2023 calendar year. The company plans to capitalize on the success of 2022, which saw the fulfillment of primary objectives.

In 2022, Lexaria introduced DehydraTECH to world-leading collaborators and explored DehydraTECH-processed CBD for the potential treatment of hypertension. The company also saw success in its research for the potential treatment of conditions such as epilepsy making the year Lexaria’s most successful yet (https://cnw.fm/KUDGq). The progress made sets the stage for the company to explore even bigger goals in 2023.

So far, animal studies have demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900% (https://cnw.fm/wju7u). In addition, in the recent EPIL-A21-1 clinical study on the use of DehydraTECH-CBD for the potential treatment of epilepsy, the technology demonstrated performance enhancements, particularly compared to one of the world’s leading anti-seizure medications, Epidiolex(R).

This, and other findings over the course of 2022, validated Lexaria’s efforts and clinical trials, reflecting the company’s commitment to addressing current underserved medical needs. It is this commitment that the company intends to pursue in the new year in what Chris Bunka, the CEO, anticipates to be the “best year ever.”

Lexaria now has its eyes set on scaling up the commercial execution of its technology. To facilitate this, it has brought on board Julian Gangolli as a Strategic Advisor. Gangolli, the former President of GW Pharmaceuticals USA, will lend his knowledge and expertise, having overseen the approval by the US Food and Drug Administration (“FDA”) of Epidiolex, the first and only pure cannabidiol (“CBD”) drug ever approved by the regulating body.

“I am excited to be advising Lexaria Bioscience as it has become an established force in the field of improved drug delivery,” Julian noted.

“As with GW Pharmaceutical’s innovations in the cannabinoid field, the potential of Lexaria’s disruptive drug delivery technology is significant and I hope to assist Lexaria in its commercial development of DehydraTECH for multiple applications,” he added (https://cnw.fm/qKar6).

Gangolli has also previously served as the North American President of Allergan and a member of their executive management team that oversaw the sale of Allergan to Actavis back in 2015, and has served as a senior member of the Allergan management team since 1998, helping to transform the company into one of the leading specialty pharmaceutical companies in the United States.

“I am very pleased to welcome Julian, with his extensive pharmaceutical experience, to the broadening Lexaria team,” noted Mr. Bunka.

With Julian’s help, Lexaria looks to achieve FDA Registration for an Investigational New Drug (“IND”) program that will kickstart a Phase 1(b) FDA-registered clinical trial exploring the safety and tolerability of DehydraTECH-CBD as a treatment for hypertension. This, the company projects will dominate the second half of the 2023 calendar year, even as the company works toward the filing of a new drug application (“NDA”) via the abbreviated 505(b)(2) pathway.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Colorado Opens Recreational Center Built Using Cannabis Taxes

Aurora, Colorado, celebrated the official opening of its new 77,000 ft2 recreational facility on Tuesday, which cost close to $42 million. The project was fully financed by tax revenue generated by legal cannabis sales.

According to KDVR news, the building is the Southeast Recreation Center and Fieldhouse and offers a variety of amenities. It includes a 23,000-foot fieldhouse with an air-conditioned interior; a complete field with turf of the highest caliber; a multipurpose gym with 8,000 feet that can hold three pickleball courts, two cross basketball courts, two volleyball courts and one main basketball court; a track that is 1/9-mile long and elevated above the gym and fitness center; and modern equipment in a 7,600-foot fitness center that includes a functional fitness area, an outdoor fitness area and a fitness studio.

Additionally, there is also a natatorium, which is made up of a 125,000-gallon swimming pool with a maximum depth of seven feet, a jet-filled spa pool, a recreational pool with a 20-foot-tall waterslide, a lazy river and a 25-yard, four-lane lap pool.

The Southeast Recreation Center, according to the city’s press release, is situated close to several neighborhoods and the Aurora Reservoir. It is anticipated that the new center will become a popular regional destination because it has the first indoor fieldhouse in the city as well as a number of other amenities and stunning views of the Colorado mountains.

The facility, which the city began construction on in early 2021, will be Aurora’s second recreational center to open in the past four years. Similar to this one, the other center, which opened in 2019 was also funded by cannabis sales tax revenue.

The opening of these two facilities with legal marijuana sales tax revenue serves as “proof of principle” for activists who worked to make Colorado one of the first two states to legalize recreational marijuana when voters passed Amendment 64 a little more than 10 years ago. Longtime proponents of marijuana legalization argued that state and local governments could economically benefit from a regulated cannabis retail market.

Colorado Governor Jared Polis, a Democrat who has worked to solidify cannabis laws, also stated that the state had done what no one had done before, making history when voters approved Amendment 64. Last summer, Polis signed an executive order to ensure that no Coloradan is prosecuted for possessing, cultivating or using marijuana, which is legal in Colorado as a result of Amendment 64.

When he signed the executive order, Polis stated that barring Coloradans from the workforce because of marijuana-related activities that are legal in Colorado but still punishable by law in other states was bad for residents, the economy and the state as a whole. He further noted that no one should face professional repercussions or be denied a professional license in Colorado if they legally consume, possess, grow or process marijuana in accordance with Colorado law. This includes people who use, possess, grow or prepare marijuana in a way that would be permitted under Colorado law in another state.

By allowing home cultivation, Colorado has paved the way for companies such as Advanced Container Technologies Inc. (OTC: ACTX), which makes indoor cultivation equipment for cannabis growing and other high-value crops, to have a bigger market to serve.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.